Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adi Diab

Showing results (101-110 of 137) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2016
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune ProfilingHeather L McArthur, Adi Diab, David B Page, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic MelanomaCaitlin A Creasy, Yuzhong Jeff Meng, Marie-Andrée Forget, et al.
The Journal of Clinical Investigation|May 13, 2022
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockadeAmber Hickman, Joost Koetsier, Trevin Kurtanich, et al.
Nature Communications|February 2, 2020
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapyMeenu Sharma, Hiep Khong, Faisal Fa'ak, et al.
Frontiers in Oncology|November 3, 2022
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanomaJoel Ho, Jane Mattei, Michael Tetzlaff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable MelanomaElizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Journal for Immunotherapy of Cancer|June 16, 2023
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse eventsFaisal Fa'ak, Maryam Buni, Adewunmi Falohun, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 8, 2021
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trialRoshal R Patel, Kewen He, Hampartsoum B Barsoumian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Pageof 14

Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2016
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune ProfilingHeather L McArthur, Adi Diab, David B Page, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic MelanomaCaitlin A Creasy, Yuzhong Jeff Meng, Marie-Andrée Forget, et al.
The Journal of Clinical Investigation|May 13, 2022
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockadeAmber Hickman, Joost Koetsier, Trevin Kurtanich, et al.
Nature Communications|February 2, 2020
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapyMeenu Sharma, Hiep Khong, Faisal Fa'ak, et al.
Frontiers in Oncology|November 3, 2022
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanomaJoel Ho, Jane Mattei, Michael Tetzlaff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable MelanomaElizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Journal for Immunotherapy of Cancer|June 16, 2023
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse eventsFaisal Fa'ak, Maryam Buni, Adewunmi Falohun, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 8, 2021
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trialRoshal R Patel, Kewen He, Hampartsoum B Barsoumian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.
Pageof 14